EGCG-Building Nanocarriers for Multitasking Drug Delivery: Design Principles, Therapeutic Opportunities, and...

Area of Science:

• Nanotechnology
• Materials Science
• Pharmacology

Background:

• Conventional nanocarriers face limitations including low drug loading, reliance on inert excipients, and potential immune responses.
• The drug loading-stability trade-off has historically constrained nanocarrier design and therapeutic efficacy.
• There is a growing need for nanocarrier systems where the carrier itself possesses therapeutic activity.

Purpose of the Study:

• To review the design principles, architectures, and functional advantages of (-)-epigallocatechin-3-gallate (EGCG)-building nanocarriers.
• To highlight the preclinical applications, particularly in cancer therapy, of these innovative nanocarrier systems.
• To discuss the challenges and opportunities for the clinical translation of EGCG-based nanocarriers.

Main Methods:

• Utilizing the unique physicochemical properties of EGCG, such as its polyphenolic structure enabling diverse molecular interactions.
• Assembling EGCG with therapeutic agents through direct association or chemical modification to form nanostructures.
• Evaluating the high drug loading capacity, reduced excipient burden, and combined therapeutic effects of EGCG-based nanocarriers.

Main Results:

• EGCG-building nanocarriers integrate structural and therapeutic functions, achieving high drug loading and reducing reliance on inert excipients.
• These systems demonstrate potential for combinational therapy by leveraging EGCG's intrinsic biological activities (antioxidant, anti-inflammatory, anticancer) alongside the loaded payload.
• EGCG nanocarriers show promise in modulating drug resistance pathways, enhancing overall therapeutic efficacy in preclinical cancer models.

Conclusions:

• EGCG-building nanocarriers represent a promising platform for advanced drug delivery, overcoming key limitations of traditional systems.
• Their ability to integrate therapeutic functions and achieve high drug loading offers significant advantages for treating diseases like cancer.
• Further research and development are crucial to address challenges and facilitate the clinical translation of EGCG-based nanocarrier technology.